A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04910568
Trial Phases:	Phase I	Protocol IDs:	GO42552 (primary) NCI-2021-07543 2021-000238-33
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genentech Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04910568

Summary

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability,
pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab
plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone
(Dd) which will be administered to participants with relapsed or refractory multiple
myeloma (R/R MM) via intravenous (IV) infusion.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.